Technology
Health
Biotechnology
Arbutus Biopharma
$1.919876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.09 (-4.50%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ABUS and other stocks, options, ETFs, and crypto commission-free!
About
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Employees
80
Headquarters
Burnaby, British Columbia
Founded
2005
Market Cap
107.45M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
357.79K
High Today
$2.02
Low Today
$1.90
Open Price
$2.00
Volume
132.70K
52 Week High
$12.60
52 Week Low
$1.90
Collections
Technology
Health
Biotechnology
2015 IPO
Canada
North America
News
Yahoo FinanceMay 13
Arbutus to Present at Upcoming May 2019 Conferences
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and CEO, will present at the following conferences in May 2019: UBS Global Healthcare Conference – New York Monday, May 20, 2019, 1:00 PM ET RBC Capital Markets Healthcare Conference – New York Tuesday, May 21, 2019, 11:00 AM ET Live webcasts of the presentations can be accessed thr...
Seeking AlphaMay 6
Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2019 Results Earnings Conference Call May 6, 2019 4:30 PM ET Company Participants Pam Murphy - IR Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - CFO Conference Call Participants Keay Nakae - Chardan Mayank Mamtani - B Riley FBR Operator Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 First Quarter Financial Results and Corporate Update Conference...
Price Paid on Robinhood
54% Lower
Right Now
52 Week Low
$1.90
Average Price Paid
$4.12
52 Week High
$12.60
Earnings
-$0.47
-$0.37
-$0.27
-$0.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, After Hours